Pay in 4 interest-free payments of $6.85 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Ethics declarations Conflict of interest The author(s) declared no potential conflicts of interest concerning this articles research, authorship, and publication
10.4161/auto.6.3.11226 Autophagy 59 CodoloG.PlotegherN.PozzobonT.BrucaleM.TessariI.BubaccoL.et al (2013)
The NDA submission was partly based on topline results from the ongoing single location BHV4157-206-RWE study (NCT06529146), in which troriluzole 200 mg administered orally once daily led to a 5070% slower rate of decline from baseline in the functional Scale for the Assessment and Rating of Ataxia (f-SARA) in all SCA genotypes at 3 years compared to an external control arm. Data from the BHV4157-206 study (NCT03701399) also demonstrated disease stabilization in the SCA3 genotype and a reduction in falls in all SCA genotypes compared to placebo over 48 weeks. If approved, troriluzole will be the first and only medication indicated for the treatment of SCA
Understanding how they compare helps you decide
US$ 25.42
US$ 28.01
US$ 24.75
US$ 23.48
US$ 23.51
